Kk Bcj 94 Drug Patent Portfolio
Kk Bcj 94 owns 1 orange book drug protected by 9 US patents Given below is the list of Kk Bcj 94's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12194025 | Pharmaceutical composition for oral administration of edaravone and method of administering same | 12 Nov, 2041 | Active |
| US12310946 | Pharmaceutical composition for oral administration of edaravone and method of administering same | 12 Nov, 2041 | Active |
| US12478611 | 12 Nov, 2041 | Active | |
| US10987341 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US11241416 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US11478450 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US11826352 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US11957660 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
| US12285409 | Edaravone suspension for oral administration | 01 Nov, 2039 | Active |
Latest Legal Activities on Kk Bcj 94's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kk Bcj 94.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
|
Recordation of Patent Grant Mailed
Critical
| 16 Apr, 2024 | US11957660 |
| Recordation of Patent eGrant | 16 Apr, 2024 | US11957660 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 Apr, 2024 | US11957660 |
|
Email Notification
Critical
| 16 Apr, 2024 | US11957660 |
| Mail Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
|
Email Notification
Critical
| 28 Mar, 2024 | US11957660 |
|
Issue Notification Mailed
Critical
| 27 Mar, 2024 | US11957660 |
| Dispatch to FDC | 21 Mar, 2024 | US11957660 |
|
Application Is Considered Ready for Issue
Critical
| 21 Mar, 2024 | US11957660 |
|
Issue Fee Payment Verified
Critical
| 20 Mar, 2024 | US11957660 |
|
Issue Fee Payment Received
Critical
| 20 Mar, 2024 | US11957660 |
|
Electronic Review
Critical
| 20 Dec, 2023 | US11957660 |
|
Email Notification
Critical
| 20 Dec, 2023 | US11957660 |
|
Mail Notice of Allowance
Critical
| 20 Dec, 2023 | US11957660 |
Kk Bcj 94's Family Patents
Kk Bcj 94 drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 26.3% of its total global patent coverage. Click
below to unlock the full patent family tree.
Kk Bcj 94 Drug List
Given below is the complete list of Kk Bcj 94's drugs and the patents protecting them.
1. Radicava Ors
Radicava Ors is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12194025 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
12 Nov, 2041
(15 years from now)
| Active |
| US12310946 | Pharmaceutical composition for oral administration of edaravone and method of administering same |
12 Nov, 2041
(15 years from now)
| Active |
| US12478611 |
12 Nov, 2041
(15 years from now)
| Active | |
| US10987341 | Edaravone suspension for oral administration |
01 Nov, 2039
(13 years from now)
| Active |
| US11241416 | Edaravone suspension for oral administration |
01 Nov, 2039
(13 years from now)
| Active |
| US11478450 | Edaravone suspension for oral administration |
01 Nov, 2039
(13 years from now)
| Active |
| US11826352 | Edaravone suspension for oral administration |
01 Nov, 2039
(13 years from now)
| Active |
| US11957660 | Edaravone suspension for oral administration |
01 Nov, 2039
(13 years from now)
| Active |
| US12285409 | Edaravone suspension for oral administration |
01 Nov, 2039
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Radicava Ors's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List